Velaglucerase Alfa Uses, Dosage, Side Effects and more
Velaglucerase Alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase Alfa has also been investigated for use in Type 3 Gaucher disease.
| Attribute | Details |
|---|---|
| Trade Name | Velaglucerase Alfa |
| Generic | Velaglucerase alfa |
| Velaglucerase alfa Other Names | GA-GCB, Velaglucerasa alfa, Velaglucerase alfa |
| Weight | 400units, |
| Type | Intravenous Powder For Injection, Intravenous |
| Formula | C2532H3850N672O711S16 |
| Weight | 63000.0 Da (approximate) |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Velaglucerase Alfa is an enzyme replacement therapy used for the long-term treatment of for pediatric and adult patients with type 1 Gaucher disease.
Velaglucerase Alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.
Velaglucerase Alfa is also used to associated treatment for these conditions: Gaucher Disease, Type 1
How Velaglucerase Alfa works
Velaglucerase Alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.
Food Interaction
No interactions found.Volume of Distribution
The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight).
Half Life
11-12 minutes.
Clearance
Mean clearance ranges from 6.72 to 7.56 mL/min/kg.
